Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

JNJJanssen Research & Development, LLCRunning, no new patients

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Non-Muscle Invasive Bladder Neoplasms

2Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • 4 insiders sold shares within a month

    Since Aug 17, 2026 · was worth 5, fading over time

    +2
Worry score2

Score over time

Stage
Phase 1/2
Patients
235 (final count)
Started
Apr 11, 2022
Main results expected
Mar 30, 2028
Fully finished
Jul 24, 2029
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Parts 1 to 3: Number of Participants with Adverse Events (AEs)

    Measured over: Up to approximately 7 years 4 months

  • Parts 1 to 3: Number of Participants with AEs by Severity

    Measured over: Up to approximately 7 years 4 months

  • Part 1: Number of Participants with Dose-limiting Toxicity (DLT)

    Measured over: Up to 28 days

  • Part 4: Overall Complete Response (CR) in Participants with Intermediate Risk-Non-Muscle Invasive Bladder Cancer (IR-NMIBC)

    Measured over: Up to approximately 7 years 4 months

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT05316155 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT05316155) ↗